en تأثیر میواینوزیتول بر پیامدهای بارداری در لقاح تزریق داخل سیتوپلاسمی اسپرم In-vitro: یک مطالعه کارآزمایی بالینی تصادفی دوسوکور Fertility & Infertility Original Article Original Article <div style="text-align: justify;"><span style="font-size:12pt"><span style="text-justify:inter-ideograph"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">مقدمه: </span></span></b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">میواینوزیتول یک واسطه درون&shy;سلولی است که در جنبه&shy;های مختلف تولید&shy;مثل در زنان نقش دارد.</span></span><span dir="LTR" style="font-size:11.0pt"><span style="font-family:"Arial","sans-serif""></span></span></span></span></span></span></span><br> <span style="font-size:12pt"><span style="text-justify:inter-ideograph"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">هدف: </span></span></b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">این مطالعه با هدف بررسی تأثیر میواینوزیتول بر پیامدهای لقاح آزمایشگاهی (</span></span><span dir="LTR" style="font-size:10.0pt">IVF</span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">)/تزریق داخل سیتوپلاسمی اسپرم (</span></span><span dir="LTR" style="font-size:10.0pt">ICSI</span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">) در زنان نابارور انجام شد.</span></span></span></span></span></span></span><br> <span style="font-size:12pt"><span style="text-justify:inter-ideograph"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">مواد و روش &shy;ها: </span></span></b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">این کارآزمایی بالینی تصادفی‌سازی شده دوسوکور بر روی 70 زن نابارور مراجعه&shy;کننده به مرکز درمان ناباروری بیمارستان بعثت سنندج برای </span></span><span dir="LTR" style="font-size:10.0pt">IVF/ICSI</span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:"> از مهر 1397 تا بهمن 1397 انجام شد. آزمودنی&shy;ها به طور تصادفی به دو گروه مداخله (36 نفر) و کنترل (34 نفر) تقسیم شدند. گروه کنترل 200 میکروگرم اسید فولیک دو بار در روز و گروه مداخله 2000 میلی&shy;گرم میواینوزیتول به همراه 200 میکروگرم اسیدفولیک دو بار در روز به مدت دو ماه در&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سیکل&shy;های </span></span><span dir="LTR" style="font-size:10.0pt">IVF/ICSI</span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:"> دریافت کردند. تعداد تخمک&shy;ها، کیفیت جنین و نتیجه </span></span><span dir="LTR" style="font-size:10.0pt">IVF/ICSI</span> <span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">مورد ارزیابی قرار گرفت.</span></span></span></span></span></span></span><br> <span style="font-size:12pt"><span style="text-justify:inter-ideograph"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">نتایج: </span></span></b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">میانگین تعداد تخمک‌ها در گروه کنترل (36/3 </span></span><span lang="FA" style="font-size:10.0pt">&plusmn;</span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:"> 83/6) کمتر از گروه مداخله ( 86/3 </span></span><span lang="FA" style="font-size:10.0pt">&plusmn;</span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:"> 67/9 ) بود (04/0 </span></span><span lang="FA" style="font-size:10.0pt">=</span><span dir="LTR" style="font-size:10.0pt">p</span> <span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">)، و تعداد تخمک‌های میوز </span></span><span dir="LTR" style="font-size:10.0pt">II</span> <span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">در گروه کنترل (50/2</span></span><span lang="FA" style="font-size:10.0pt"> &plusmn;</span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:"> 43/5) کمتر از گروه مداخله (71/3</span></span><span lang="FA" style="font-size:10.0pt"> &plusmn;</span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:"> 53/7) بود (04/0 </span></span><span lang="FA" style="font-size:10.0pt">=</span><span dir="LTR" style="font-size:10.0pt">p</span> <span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">). درصد بارداری بالینی در گروه کنترل (33/23%) کمتر از گروه مداخله (66/56%) بود (04/0 </span></span><span lang="FA" style="font-size:10.0pt">=</span><span dir="LTR" style="font-size:10.0pt">p</span> <span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">). درصد تولد زنده در گروه شاهد و مداخله به ترتیب 10 و 66/26 درصد بود (04/0 </span></span><span lang="FA" style="font-size:10.0pt">=</span><span dir="LTR" style="font-size:10.0pt">p</span> <span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">).</span></span></span></span></span></span></span><br> <b><span dir="RTL" lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">نتیجه &shy;گیری:</span></span></b> <span dir="RTL" lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">تجویز میواینوزیتول با افزایش تعداد تخمک‌های کل و میوز </span></span><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times="">II</span></span> <span dir="RTL" lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">در زنان نابارور که تحت </span></span><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times="">IVF/ICSI</span></span><span dir="RTL" lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:"> قرار می‌گیرند، ممکن است بارداری بالینی و نرخ تولد زنده را افزایش دهد.</span></span></div> <div style="text-align: justify;"><span style="font-size:11pt"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Background: </span></span></b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Myo-inositol is an intracellular mediator which is involved in various aspects of reproduction in women. </span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Objective:</span></span></b> <span style="font-size:12.0pt"><span style="background:white"><span new="" roman="" style="font-family:" times="">This study aimed to evaluate the impact of Myo-inositol on the outcomes of in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles in infertile women. </span></span></span><span style="font-size:12.0pt"><span style="font-family:"Times New Roman","serif""></span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:12.0pt"><span style="background:white"><span new="" roman="" style="font-family:" times="">Materials and Methods: </span></span></span></b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">This double-blind randomized controlled trial was conducted on 70 infertile women referred to the Infertility Treatment Center, Besat hospital, Sanandaj, Iran from May 2019 to September 2019 for IVF/ICSI cycles.</span></span><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""> <span style="background:white">The participants were randomly </span></span></span><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">divided </span></span><span style="font-size:12.0pt"><span style="background:white"><span new="" roman="" style="font-family:" times="">into 2 intervention (n = 36) and control (n = 34) groups</span></span></span><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">. The intervention group received 2000 mg of Myo-inositol and 200 mcg folic acid twice a day for 2 months and the control group received 200 mcg of folic acid </span></span><span class="fontstyle01" serif="" style="font-family:Times-Roman,"><span style="color:#242021"><span style="font-weight:normal"><span style="font-style:normal"><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">twice a day</span></span></span></span></span></span><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""> <span class="fontstyle01" serif="" style="font-family:Times-Roman,"><span style="color:#242021"><span style="font-weight:normal"><span style="font-style:normal"><span new="" roman="" style="font-family:" times="">for 2 months</span></span></span></span></span></span></span><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""> in the IVF/ICSI cycles (from the third day of cycle until the end of the second month).</span></span> <span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Finally, the number of oocytes, the quality of embryos, and the IVF/ICSI outcomes were compared between the 2 groups. </span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Results:</span></span></b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""> The mean numbers of oocytes, MII oocytes, and 2 pronuclear embryos were significantly higher in the intervention group than the control group. Also, the clinical pregnancy and live birth rates in the intervention group were significantly higher than in the controls (p = 0.04). </span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Conclusion:</span></span></b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""> The administration of Myo-inositol may increase clinical pregnancy and live birth rates by increasing the number of total and meiosis II oocytes in infertile women undergoing IVF/ICSI. </span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif""></span></span></span></span></span></div> ناباروری, لقاح آزمایشگاهی, تزریق داخل سیتوپلاسمی اسپرم, میواینوزیتول. Infertility, In vitro fertilization, Intracytoplasmic sperm injection, Myo-inositol. 643 650 http://ijrm.ir/browse.php?a_code=A-10-1650-1&slc_lang=en&sid=1 Fariba Seyedoshohadaei f.seyedoshohadaei@muk.ac.ir 0000-0003-3673-8317 No Department of Obstetrics and Gynecology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. Infertility Treatment Center of Besat Hospital, Kurdistan University of Medical Sciences, Sanandaj, Iran. Shahin Abbasi s.abbasi@muk.ac.ir 0000-0001-9665-8103 Yes Department of Obstetrics and Gynecology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. Masomeh Rezaie masumeh.rezaii66@gmail.com 0000-0003-2455-3593 No Department of Obstetrics and Gynecology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. Infertility Treatment Center of Besat Hospital, Kurdistan University of Medical Sciences, Sanandaj, Iran. Azra Allahvaisi azraalahvaisij@gmail.com 0000-0003-4227-1290 No Infertility Treatment Center of Besat Hospital, Kurdistan University of Medical Sciences, Sanandaj, Iran. Department of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. Mohammad Jafar Rezaie jafggg@gmail.com 0000-0001-7332-1217 No Infertility Treatment Center of Besat Hospital, Kurdistan University of Medical Sciences, Sanandaj, Iran. Department of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. Nasrin Soufizade sufizad1@gmail.com 0000-0001-8326-1422 No Department of Obstetrics and Gynecology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. Khaled Rahmani khaledrahmani1@yahoo.com 0000-0002-0860-8040 No Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.